High-dose Etoposide Could Discriminate Patients With Refractory/Relapsed Lymphoma Benefit From APBSCT

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2016

Conditions

Lymphoma

Interventions

DRUG

high-dose etoposide

an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.

All Listed Sponsors

lead

Yang Jun

OTHER

NCT03130582 - High-dose Etoposide Could Discriminate Patients With Refractory/Relapsed Lymphoma Benefit From APBSCT | Biotech Hunter | Biotech Hunter